Weekly Recap | TAK.US +5.02%, most brokers rate it buyWeekly Review·Oct 17, 2026 at 08:15 AMTAK+2.16%
Weekly Recap | TAK.US +3.56%, FDA priority review for pipeline assetWeekly Review·Sep 19, 2026 at 06:58 AMTAK+2.16%
